(Q39751709)

14 September 2017

title

Access to highly active antiretroviral therapy for injection drug users: adherence, resistance, and death (English)

1 reference

14 September 2017

main subject

anti-retroviral agent

0 references

2

David D Celentano

1 reference

14 September 2017

1

David Vlahov

1 reference

14 September 2017

publication date

5 April 2006

1 reference

Cadernos de saúde pública

14 September 2017

published in

1 reference

14 September 2017

volume

22

1 reference

14 September 2017

issue

4

1 reference

14 September 2017

page(s)

705-718

1 reference

Sharing of noninjection drug-use implements as a risk factor for hepatitis C.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Cognitive impairment in substance abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

In vivo effects of cocaine on immune cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Global overview of injecting drug use and HIV infection among injecting drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Crystal methamphetamine use predicts incident STD infection among men who have sex with men recruited online: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Longitudinal patterns of methamphetamine, popper (amyl nitrite), and cocaine use and high-risk sexual behavior among a cohort of san francisco men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Why HIV infections have increased among men who have sex with men and what to do about it: findings from California focus groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Risk Factors for Rectal Gonococcal Infection Amidst Resurgence in HIV Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A comparison of injection and non-injection methamphetamine-using HIV positive men who have sex with men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Seroprevalence of and risk factors for HIV-1 infection among South American men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Stimulant abuse treatment as HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

"Have a piss, drink ogogoro, smoke igbo, but don't take gbana"--hard and soft drugs in Nigeria: a critical comparison of official policies and the view on the street

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Psychoactive substance abuse among inmates of a Nigerian prison population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Effectiveness of psychosocial interventions in preventing HIV risk behaviour in injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Structural interventions to reduce HIV transmission among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Community-based intervention to reduce demand for drugs in Northern Thai tribal villages

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

The community health advisor program and the deep South network for cancer control: health promotion programs for volunteer community health advisors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A multicommunity trial for primary prevention of adolescent drug abuse. Effects on drug use prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Community-based trial to prevent drug use among youths in Yunnan, China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A rapid assessment of community-wide HIV/STI intervention in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Long-term trends in self-reported HIV risk behavior: injection drug users in Los Angeles, 1987 through 1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Barriers to use of free antiretroviral therapy in injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Self-reported antiretroviral therapy in injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Clinical experience and choice of drug therapy for human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Ability of primary care physicians to recognize physical findings associated with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Protease inhibitors in the homeless

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Strategies for long-term success in the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A prospective study of predictors of adherence to combination antiretroviral medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Drug abuse treatment as an HIV prevention strategy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the Healthy Living Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Medication Adherence Among HIV-Infected Patients: Understanding the Complex Behavior of Patients Taking This Complex Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Patient adherence to HIV medication regimens: a review of published and abstract reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Protease inhibitor combination therapies and perceptions of gay men regarding AIDS severity and the need to maintain safer sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Highly active antiretroviral therapy (HAART). Awareness and beliefs about infectivity and the influence on sexual behaviour in the general population of Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

HIV-1 drug resistance in newly infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

High-risk behavior and potential transmission of drug-resistant HIV among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A model for the delivery of care for HIV-positive clients

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Injection and Syringe Sharing Among HIV-Infected Injection Drug Users: Implications for Prevention of HIV Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Barebacking among gay and bisexual men in New York City: explanations for the emergence of intentional unsafe behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Alcohol and public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

How effective are risk-reduction interventions targeting injecting drug users?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Community-level interventions are needed to prevent new HIV infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

AIDS risk reduction: a community health education intervention for minority high risk group members.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Correlates of the sustainability of community-based heart health promotion interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Changes in HIV seroprevalence and related behaviors among male injection drug users who do and do not have sex with men: New York City, 1990-1999

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

The era of adherence to HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Viral load, perceived infectivity, and unprotected intercourse

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0102-311X2006000400002

10.1590/S0102-311X2006000400002

21 January 2018

Identifiers

DOI

1 reference

release_6fx2gngtrvampp4jf5uoq2s3vy

14 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6fx2gngtrvampp4jf5uoq2s3vy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference